EUCTR2005-003957-28-DK进行中（未招募）不适用
FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMISEDACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILESYSTEMIC LUPUS ERYTHEMATOSUS NEPHRITIS: ORALCYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUSCYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUSCYCLOPHOSPHAMIDE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 141
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Newly diagnosed children with untreated and biopsy proven revised WHO Class III, IV
- •proliferative lupus nephritis and 24 hour proteinuria = 500 mg/day. The kidney biopsy
- •specimen will be read by the renal pathologists of the participating centres (light and
- •immunofluorescence) (54). Slides of paraffin-embedded sections from all patients will
- •be re-viewed by a blinded a renal pathologist at the PRINTO coordinating centre.
- •2) Diagnosis of JSLE according to the ACR revised classification criteria (57);
- •3) Age at enrolment = 18 years.
- •4) Female of child-bearing potential must have a negative pregnancy test at the beginning
- •of the trial, and then every 3 months. If sexually active, they must agree to use adequate
- •contraception, throughout study participation, and must have no intention of conceiving
- •during the course of the study. Post-pubertal males must have no plans to father a child
- •during the study and agree to use adequate birth control methods if sexually active.
- •5) Ability to comply with the entire study procedures, ability to communicate
- •meaningfully with the investigational staff, competence to give written informed
- •consent; to be applied to the parents and/or patients, as appropriate
- •6)Duly executed, written, informed consent obtained from the parents or other legal
- •representative and/or the patient according to requirement of the local ethics committee.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Treatment with the CYC, AZA or mycophenolate mofetil anytime before randomisation.
- •2) Neutrophil count <1,500 cell/mm3 and/or platelet count <50,000/mm3.
- •3) History of poor compliance with previous treatment.
- •4) Evidence of current use of alcohol or illicit drugs abuse.
- •5) Live vaccines not allowed during the entire duration of the trial.
研究者
相似试验
进行中（未招募）
不适用
FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE PLUS METHOTREXATE - NDEUCTR2005-003956-37-ITISTITUTO GIANNINA GASLINI132
进行中（未招募）
不适用
Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexateJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-SEIstituto Giannina Gaslini132
进行中（未招募）
不适用
Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisolone versus prednisone plus cyclosporine A versus prednisone plus methotrexateJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-GBIstituto Giannina Gaslini132
进行中（未招募）
不适用
Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate - PRINTO JDM TrialJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-BEniversity Hospital Gent180
进行中（未招募）
1 期
Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexateJuvenile Dermatomyositis at onsetEUCTR2005-003956-37-DKIstituto Giannina Gaslini132